Pharmaceutical
ChemLinkedMarketChemicalFoodCosmeticPharmaceuticalJapanAgrochemicalSustainability
News
Comprehensive coverage on the latest pharmaceutical regulatory update and industry activities in China.
INDUSTRY
Marketing Approval Innovative Drug Diabetes Drug Registration New Drug
[Updated] GLP-1-RAs Swoop to Chinese Market, Eyeing Diabetes Treatment & Weight Control Needs On July 25, 2023, China National Medical Products Administration (NMPA) approved Beinaglutide Injection (Feisumei), a glucagon-like peptide-1 receptor agonist (GLP-1-RA), for weight loss.
Aug 23, 2023
INDUSTRY
Marketing Approval Priority Review Generic Drug Diabetes Drug Registration New Drug
Monthly Report: New Drug Approvals in China | July 2023 In July 2023, China NMPA approved 5 new drugs, among which 3 are chemical drugs and 2 are biological products.
Aug 03, 2023
INDUSTRY
Marketing Approval Priority Review Innovative Drug Generic Drug Biological Product Cancer Diabetes Drug Registration New Drug
Monthly Report: New Drug Approvals in China | June 2023 In June 2023, China NMPA approved 33 new drugs, among which 26 are chemical drugs while 7 are biological products.
Jul 07, 2023
INDUSTRY
Marketing Approval Innovative Drug Generic Drug Biological Product Cancer Diabetes Vaccine Drug Registration New Drug
Monthly Report: New Drug Approvals in China | May 2023 In May 2023, China NMPA approved 27 new drugs, among which 16 are chemicals and 11 are biologics: 1. Betta Pharma’ Befotertinib Mesylate Capsules; 2. Sanhome Pharma’s Alfosbuvir Tablets; 3. Novartis’ Ribociclib Succinate Tablets...
Jun 12, 2023
INDUSTRY
Marketing Approval Priority Review Innovative Drug Cancer Diabetes Drug Registration New Drug
Monthly Report: New Drug Approvals in China | October 2022 In October 2022, China NMPA approved 17 new drugs, including 11 chemical drugs and 6 biological products.
Nov 03, 2022
INDUSTRY
Marketing Approval Priority Review Innovative Drug Generic Drug Biological Product Cancer Diabetes Drug Registration New Drug
Monthly Report: New Drug Approvals in China | September 2022 In September 2022, China NMPA approved 16 new drugs, including 12 chemical drugs and 4 biological products.
Oct 08, 2022
INDUSTRY
MAH Marketing Approval Priority Review Innovative Drug Generic Drug Biological Product Diabetes Rare Disease Drug Registration New Drug
Monthly Report: New Drug Approvals in China | August 2022 In August 2022, China NMPA approved 13 new drugs, including 9 chemical drugs and 4 biological products. Among them, MSD's HPV 9-valent vaccine got approval to expand the target group from females 16-26 years of age to 9-45 years of age.
Sep 09, 2022
INDUSTRY
Volume-based Procurement Diabetes
How China's Volume-based Procurements (VBPs) Impact Diabetes Medicine Market A total of 27 diabetes drugs, including Empagliflozin, Canagliflozin, and Glipizide, have entered China's national volume-based procurements (VBPs).
Aug 11, 2022
Most Popular